INTRODUCTION
Breast cancer (BC) is the most prevalent cancer among women in developed and developing countries. Human epidermal growth factor receptor 2 (HER2)-positive clinical subtype of BC has an adverse prognosis with lower rates of disease-free survival (DFS) and overall survival (OS). Trastuzumab was the first agent specifically targeting the HER2 protein. Its combination with chemotherapy significantly improved the DFS and OS of patients with metastatic and early HER2-positive BC. Pertuzumab is a new HER2-targeted drug developed for use in combination with trastuzumab and chemotherapy. The clinical effectiveness of this dual targeted therapy in comparison with combination of trastuzumab and chemotherapy was demonstrated for metastatic BC in CLEOPATRA trial and for less advanced disease in NeoSphere trial, where it was studied in neoadjuvant setting.
OBJECTIVES
To assess the cost-utility of pertuzumab added to neoadjuvant treatment with trastuzumab and docetaxel for patients with locally advanced, inflammatory, or early HER2-positive BC in Russia.
METHODS
Analysis was performed from the perspective of health care payer, comparing neoadjuvant treatment with pertuzumab+trastuzumab+docetaxel and trastuzumab+docetaxel. We developed Markov model with three states: «Progression-free», «Progression» and «Death», with life time horizon and cycle length of 4 weeks. Modelled population was assumed to be the same as in in NeoSphere trial [1] . All patients started in the "Progressionfree" state, where they could stay or move to "Progression" with the probability calculated on the basis of progression-free survival in NeoSphere trial [2] . Both states were associated with the risk of death. Probability of death in progression was derived from the publication by Slamon et al, who studied treatment of progressive metastatic HER-2 positive BC [3] , and in no-progression state it was the same as in general population (Figure 1 ). The process was repeated for 28 years, as the median age of the modelled population was 50 years and life expectancy for women at this age in Russia was 78 years. Utilities were derived from published literature [4] . Only costs of chemotherapy were included into the model, based on treatment regimens in NeoSphere trial, real practice data on treatment of metastatic HER2-positive BC in Russia and registered prices for medications. Costs and benefits were discounted at 3,5%. Costs were converted into EURO using the average annual exchange rate in 2015 (1 EURO=67.7767 RUR). All key model inputs are presented in Table 1 .
RESULTS
The results of modelling demonstrated that costs for cohort of patients treated with neoadjuvant pertuzumab, trastuzumab and docetaxel were higher (€52,901 vs €37,353), and additional 1.06 QALY were gained. ICER was €14,645 per QALY, which is below the willingness to pay threshold often mentioned in Russia (though not officially accepted) -three times the national annual GDP per capita, €24,344 in 2015 - Table 2 . Probabilistic sensitivity analysis (1000 simulations) showed that addition of pertuzumab to neoadjuvant treatment was more effective in 83% simulations and remained a cost-effective option in 63,4% simulations (Figure 2) .
CONCLUSION
There is a high probability that neoadjuvant treatment with pertuzumab, trastuzumab and docetaxel is an efficient option for treating patients with locally advanced, inflammatory, or early HER2-positive breast cancer in Russian health care setting 
